Yoon Soo-Young, Jeong Su Jin, Kim Jin Sug, Hwang Hyeon Seok, Jeong Kyunghwan
Division of Nephrology, Department of Internal Medicine, Kyung Hee University College of Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea,
Statistics Support Part, Medical Science Research Institute, Kyung Hee University, Seoul, Republic of Korea.
Am J Nephrol. 2025 May 19:1-12. doi: 10.1159/000546380.
Time in target range of systolic blood pressure (SBP-TTR) is the percentage of time that the SBP remains within 110-130 mm Hg. The association between the SBP-TTR and clinical outcomes in patients with chronic kidney disease (CKD) remains unclear. We evaluated the risks of cardiovascular disease (CVD), all-cause mortality, and renal events across the SBP-TTR groups.
Overall, 193,289 patients with CKD who underwent at least two health checkups between 2012 and 2015 were selected from the Korean National Health Insurance Database. The patients were categorized into three categories based on their SBP-TTR levels: 76-100%, 26-75%, and 0-25%. The primary outcome was CVD risk and the secondary outcomes were all-cause mortality and progression to end-stage kidney disease (ESKD) according to SBP-TTR using Cox regression analysis.
Compared with patients with SBP-TTR of 76-100%, the adjusted hazard ratios (HRs) for CVD were 1.07 (95% confidence interval [CI], 1.03-1.10) and 1.09 (95% CI: 1.06-1.13) for patients with SBP-TTR of 26-75%, and 0-25%, respectively. The adjusted HR for all-cause mortality was 1.04 (95% CI: 1.003-1.07) and 1.37 (95% CI: 1.28-1.46) for patients with SBP-TTR of 26-75% and 0-25%, respectively. The adjusted HRs for ESKD progression increased gradually: 1.14-fold (95% CI: 1.07-1.21) for the SBP-TTR 26-75% group and 1.37-fold (95% CI: 1.28-1.46) for the SBP-TTR 0-25% group. For patients not taking antihypertensive medications, a lower SBP-TTR was associated with a higher risk of CVD events and ESKD progression than in those taking antihypertensive medications.
Among patients with CKD, those with a lower SBP-TTR had a higher risk of cardiovascular events, mortality, and progression to ESKD.
收缩压处于目标范围内的时间(SBP-TTR)是指收缩压维持在110-130 mmHg之间的时间百分比。慢性肾脏病(CKD)患者的SBP-TTR与临床结局之间的关联尚不清楚。我们评估了不同SBP-TTR组中心血管疾病(CVD)、全因死亡率和肾脏事件的风险。
总体而言,从韩国国民健康保险数据库中选取了193289例在2012年至2015年期间至少接受过两次健康检查的CKD患者。根据他们的SBP-TTR水平将患者分为三类:76-100%、26-75%和0-25%。主要结局是CVD风险,次要结局是根据SBP-TTR采用Cox回归分析得出的全因死亡率和进展至终末期肾病(ESKD)。
与SBP-TTR为76-100%的患者相比,SBP-TTR为26-75%和0-25%的患者发生CVD的校正风险比(HR)分别为1.07(95%置信区间[CI],1.03-1.10)和1.09(95%CI:1.06-1.13)。SBP-TTR为26-75%和0-25%的患者全因死亡率的校正HR分别为1.04(95%CI:1.003-1.07)和1.37(95%CI:1.28-1.46)。ESKD进展的校正HR逐渐增加:SBP-TTR 26-75%组为1.14倍(95%CI:1.07-1.21),SBP-TTR 0-25%组为1.37倍(95%CI:1.2-1.46)。对于未服用抗高血压药物的患者,较低的SBP-TTR与CVD事件和ESKD进展风险较高相关,高于服用抗高血压药物的患者。
在CKD患者中,SBP-TTR较低的患者发生心血管事件、死亡和进展至ESKD的风险较高。